Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Johnson & Johnson (JNJ)

Johnson & Johnson EVP Jennifer Taubert to retire; Tom Cavanaugh named successor

Neutral Impact 3 of 5 leadership Written later

Johnson & Johnson said Executive Vice President Jennifer Taubert will retire as Worldwide Chairman, Innovative Medicine, effective September 1, 2026, after more than 21 years with the company. Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her and join the Executive Committee on the same date. The company says Innovative Medicine grew to more than $60 billion in annual revenue under Taubert's leadership, but the filing gives no figures on how the transition will affect results.

Key points

  • Jennifer Taubert retires as EVP, Worldwide Chairman, Innovative Medicine, effective September 1, 2026
  • Tom Cavanaugh succeeds her and joins the Executive Committee effective September 1, 2026
  • Cavanaugh joined Johnson & Johnson in 2017 and previously spent nearly 15 years at Celgene
  • Taubert had a tenure of over 21 years at Johnson & Johnson; the unit she led had more than $60 billion in annual revenue

The filing

CompanyJohnson & Johnson (JNJ)
Form8-K, current report
Filed with the SECAug 4, 2026, 8:48 AM ET
Accession number0000200406-26-000167

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.